

Konstantinos V Floros

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9534635/publications.pdf>

Version: 2024-02-01

26
papers

1,138
citations

471509

17
h-index

610901

24
g-index

27
all docs

27
docs citations

27
times ranked

2360
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitochondrial Shape Governs BAX-Induced Membrane Permeabilization and Apoptosis. <i>Molecular Cell</i> , 2015, 57, 69-82.	9.7	174
2	Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i> -Mutant Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 754-769.	9.4	132
3	Exploitation of the Apoptosis-Primed State of MYCN-Amplified Neuroblastoma to Develop a Potent and Specific Targeted Therapy Combination. <i>Cancer Cell</i> , 2016, 29, 159-172.	16.8	104
4	Venetoclax Is Effective in Small-Cell Lung Cancers with High BCL-2 Expression. <i>Clinical Cancer Research</i> , 2018, 24, 360-369.	7.0	96
5	The Role of BH3-Only Proteins in Tumor Cell Development, Signaling, and Treatment. <i>Genes and Cancer</i> , 2011, 2, 523-537.	1.9	92
6	Epithelial-to-Mesenchymal Transition Antagonizes Response to Targeted Therapies in Lung Cancer by Suppressing BIM. <i>Clinical Cancer Research</i> , 2018, 24, 197-208.	7.0	74
7	<i>MYCN</i> -Amplified Neuroblastoma Is Addicted to Iron and Vulnerable to Inhibition of the System Xc ⁻ /Glutathione Axis. <i>Cancer Research</i> , 2021, 81, 1896-1908.	0.9	73
8	Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	70
9	BAK/BAX activation and cytochrome c release assays using isolated mitochondria. <i>Methods</i> , 2013, 61, 146-155.	3.8	49
10	Cisplatin-Induced Apoptosis in HL-60 Human Promyelocytic Leukemia Cells. <i>Annals of the New York Academy of Sciences</i> , 2003, 1010, 153-158.	3.8	43
11	Alterations in mRNA Expression of Apoptosis-Related Genes BCL2, BAX, FAS, Caspase-3, and the Novel Member BCL2L12 after Treatment of Human Leukemic Cell Line HL60 with the Antineoplastic Agent Etoposide. <i>Annals of the New York Academy of Sciences</i> , 2006, 1090, 89-97.	3.8	42
12	mRNA expression analysis of a variety of apoptosis-related genes, including the novel gene of the BCL2-family, BCL2L12, in HL-60 leukemia cells after treatment with carboplatin and doxorubicin. <i>Biological Chemistry</i> , 2004, 385, 1099-103.	2.5	33
13	The Ewing Family of Tumors Relies on BCL-2 and BCL-XL to Escape PARP Inhibitor Toxicity. <i>Clinical Cancer Research</i> , 2019, 25, 1664-1675.	7.0	26
14	Coamplification of <i>miR-4728</i> protects <i>HER2</i> -amplified breast cancers from targeted therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E2594-E2603.	7.1	23
15	Sensitization to the mitochondrial pathway of apoptosis augments melanoma tumor cell responses to conventional chemotherapeutic regimens. <i>Cell Death and Disease</i> , 2012, 3, e420-e420.	6.3	22
16	Topotecan and methotrexate alter expression of the apoptosis-related genes BCL2, FAS and BCL2L12 in leukemic HL-60 cells. <i>Biological Chemistry</i> , 2006, 387, 1629-33.	2.5	19
17	Molecular Response of HL-60 Cells to Mitotic Inhibitors Vincristine and Taxol Visualized with Apoptosis-Related Gene Expressions, Including the New Member <i>BCL2L12</i> . <i>Annals of the New York Academy of Sciences</i> , 2009, 1171, 276-283.	3.8	18
18	Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. <i>Cell Death and Disease</i> , 2021, 12, 179.	6.3	11

#	ARTICLE	IF	CITATIONS
19	Overexpression of the novel member of the BCL2 gene family, BCL2L12, is associated with the disease outcome in patients with acute myeloid leukemia. <i>Clinical Biochemistry</i> , 2012, 45, 1362-1367.	1.9	10
20	Catastrophic ATP loss underlies a metabolic combination therapy tailored for MYCN-amplified neuroblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	10
21	Unmasking BCL-2 Addiction in Synovial Sarcoma by Overcoming Low NOXA. <i>Cancers</i> , 2021, 13, 2310.	3.7	6
22	MYCN upregulates the transsulfuration pathway to suppress the ferroptotic vulnerability in MYCN-amplified neuroblastoma. <i>Cell Stress</i> , 2022, 6, 21-29.	3.2	5
23	Investigating New Mechanisms of Acquired Resistance to Targeted Therapies: If You Hit Them Harder, Do They Get Up Differently?. <i>Cancer Research</i> , 2020, 80, 25-26.	0.9	4
24	Evaluation of combined BCL-2/MCL-1 inhibition as a therapeutic approach for synovial sarcoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, e23561-e23561.	1.6	2
25	One gene to rule them all and in the darkness bind them. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1465881.	0.7	0
26	Sensitivity and Resistance to BH3 Mimetics in Cancer Therapy. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2018, , 147-180.	0.1	0